|Bid||56.26 x 800|
|Ask||56.49 x 800|
|Day's Range||56.03 - 57.17|
|52 Week Range||21.98 - 82.49|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 30, 2017 - Jun 2, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.67|
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Aug. 20, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the promotions of Sander van Deventer, M.D., Ph.D., to Executive Vice President, Research and Product Development, and Alex Kuta, Ph.D., to Executive Vice President, Operations, effective immediately. As a result of these changes, the Company is eliminating the Chief Operating Officer role, and Scott McMillan, Ph.D., will be retiring from uniQure. “With the promotions of Sander and Alex, we are recognizing the demonstrated track-records and exceptional leadership that each has provided as we advance uniQure’s pipeline of novel gene therapies,” stated Matt Kapusta, chief executive officer of uniQure.
"If the products that the (FDA) is approving aren't standing the test of time, are they going to become more tentative with drug approvals? (Cell and gene therapies) may bring that issue to the forefront," one regulatory expert said.
It might be of some concern to shareholders to see the uniQure N.V. (NASDAQ:QURE) share price down 22% in the last...
uniQure (QURE) delivered earnings and revenue surprises of -10.67% and 61.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
~ Presented 36 Weeks of Follow-up Data from Phase IIb Study of AMT-061 Demonstrating Sustained Increases in FIX Activity at up to 54% of Normal ~ ~ Continuing Patient.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, July 26, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
CEO, CFO, Managing Director of Uniqure Nv (30-Year Financial, Insider Trades) Matthew C Kapusta (insider trades) sold 8,000 shares of QURE on 07/17/2019 at an average price of $71.45 a share. Continue reading...
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
~ FIX Activity Up to 54% of Normal, with Mean of 45% of Normal, at 36 WeeksAfter Administration of AMT-061 in Phase IIb Study ~ ~ Clinical Benefit and Tolerability of.
Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector. Here ...
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 21, 2019 -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients.
A few biotechs focused on oncology or gene therapies are potential acquisition targets following the announcement by Pfizer to acquire Array BioPharma.
Gene therapy player Uniqure could head to the auction block, an analyst said Monday as shares of the biotech company popped. He also said Roche's plan to buy Spark Therapeutics could falter.
jumped Monday after a report said the biotechnology company was exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy. UniQure is working with advisers as it weighs options including a sale or partnerships, Bloomberg reported, citing people with knowledge of the matter. UniQure developed Glybera, the first gene therapy approved for sale in Europe, though the $1 million treatment had disappointing sales and the company said it wouldn't renew its marketing authorization in 2017.
These four stocks in the high-momentum technology, biotech and mining areas are on the move. Advanced Micro Devices (AMD) leapt $1.99 to $29.57 on 107 million shares Tuesday. On Monday the chip maker announced a deal to license its custom graphics intellectual property to Samsung for use in mobile devices.
In this article we are going to estimate the intrinsic value of uniQure N.V. (NASDAQ:QURE) by taking the expected...